Development
Cullinan Therapeutics, Inc.
CGEM
$7.85
-$0.235-2.91%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -153.16M | -156.14M | -141.76M | 65.35M | 111.21M |
| Total Depreciation and Amortization | 310.00K | 292.00K | 221.00K | 152.00K | 93.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.92M | 23.38M | 23.60M | -230.58M | -249.15M |
| Change in Net Operating Assets | -339.00K | -8.66M | -43.39M | 9.33M | 11.18M |
| Cash from Operations | -134.28M | -141.13M | -161.34M | -155.75M | -126.66M |
| Capital Expenditure | -208.00K | -1.09M | -1.34M | -1.29M | -1.13M |
| Sale of Property, Plant, and Equipment | -- | 91.00K | 91.00K | 91.00K | 91.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 5.00M | 275.00M | 275.00M |
| Other Investing Activities | 36.01M | -43.28M | -63.04M | -44.35M | -24.98M |
| Cash from Investing | 35.81M | -44.27M | -59.29M | 229.45M | 248.98M |
| Total Debt Issued | 1.83M | 2.00M | 2.00M | 3.40M | 2.38M |
| Total Debt Repaid | -- | 0.00 | 0.00 | -2.20M | -2.20M |
| Issuance of Common Stock | 38.93M | 38.87M | 40.19M | 4.43M | 6.02M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -33.28M | -33.28M | -33.32M | -32.13M |
| Cash from Financing | 40.75M | 7.59M | 8.90M | -27.69M | -25.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -57.72M | -177.81M | -211.73M | 46.01M | 96.38M |